Jilin Province Huinan Changlong Bio-pharmacy Company Limited (8049.HK)
HKD 1.39
(-0.71%)
HKD 1.39
(-0.71%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | 148.2 Million CNY | -23.43% |
| 2022 | 193.56 Million CNY | 35.09% |
| 2021 | 143.28 Million CNY | 13.22% |
| 2020 | 126.55 Million CNY | -12.55% |
| 2019 | 144.72 Million CNY | -10.23% |
| 2018 | 161.21 Million CNY | 11.64% |
| 2017 | 144.4 Million CNY | 1.21% |
| 2016 | 142.67 Million CNY | 21.28% |
| 2015 | 117.63 Million CNY | -11.41% |
| 2014 | 132.78 Million CNY | 67.5% |
| 2013 | 79.27 Million CNY | 34.93% |
| 2012 | 58.75 Million CNY | 15.45% |
| 2011 | 50.89 Million CNY | 41.8% |
| 2010 | 35.89 Million CNY | 62.58% |
| 2009 | 22.07 Million CNY | 47.28% |
| 2008 | 14.98 Million CNY | 21.09% |
| 2007 | 12.37 Million CNY | 307.57% |
| 2006 | 3.03 Million CNY | -62.12% |
| 2005 | 8.01 Million CNY | -6.81% |
| 2004 | 8.6 Million CNY | -1.19% |
| 2003 | 8.7 Million CNY | -17.76% |
| 2002 | 10.58 Million CNY | -61.34% |
| 2001 | 27.38 Million CNY | -19.66% |
| 2000 | 34.08 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | 52.14 Million CNY | 0.0% |
| 2024 Q1 | 52.14 Million CNY | 249.66% |
| 2023 Q3 | 52.44 Million CNY | 84.28% |
| 2023 Q1 | 52.38 Million CNY | -41.08% |
| 2023 Q2 | 28.46 Million CNY | -45.67% |
| 2023 FY | 148.2 Million CNY | -23.43% |
| 2023 Q4 | 14.91 Million CNY | -71.57% |
| 2022 FY | 193.56 Million CNY | 35.09% |
| 2022 Q3 | 27.4 Million CNY | -37.21% |
| 2022 Q4 | 88.9 Million CNY | 224.44% |
| 2022 Q1 | 33.61 Million CNY | -27.42% |
| 2022 Q2 | 43.64 Million CNY | 29.82% |
| 2021 Q1 | 20.1 Million CNY | -53.81% |
| 2021 Q3 | 47.99 Million CNY | 66.24% |
| 2021 FY | 143.28 Million CNY | 13.22% |
| 2021 Q4 | 46.31 Million CNY | -3.5% |
| 2021 Q2 | 28.86 Million CNY | 43.57% |
| 2020 Q1 | 13.87 Million CNY | -75.5% |
| 2020 Q2 | 37.81 Million CNY | 172.65% |
| 2020 Q3 | 31.34 Million CNY | -17.12% |
| 2020 Q4 | 43.53 Million CNY | 38.89% |
| 2020 FY | 126.55 Million CNY | -12.55% |
| 2019 FY | 144.72 Million CNY | -10.23% |
| 2019 Q4 | 56.61 Million CNY | 63.48% |
| 2019 Q3 | 34.63 Million CNY | -9.36% |
| 2019 Q1 | 15.26 Million CNY | -77.98% |
| 2019 Q2 | 38.21 Million CNY | 150.39% |
| 2018 FY | 161.21 Million CNY | 11.64% |
| 2018 Q3 | 36.37 Million CNY | -0.65% |
| 2018 Q4 | 69.31 Million CNY | 90.54% |
| 2018 Q2 | 36.61 Million CNY | 93.69% |
| 2018 Q1 | 18.9 Million CNY | -64.04% |
| 2017 Q2 | 37.51 Million CNY | 109.0% |
| 2017 Q3 | 36.36 Million CNY | -3.04% |
| 2017 FY | 144.4 Million CNY | 1.21% |
| 2017 Q4 | 52.57 Million CNY | 44.56% |
| 2017 Q1 | 17.94 Million CNY | -66.99% |
| 2016 FY | 142.67 Million CNY | 21.28% |
| 2016 Q4 | 54.37 Million CNY | 53.82% |
| 2016 Q3 | 35.34 Million CNY | -1.91% |
| 2016 Q2 | 36.03 Million CNY | 113.0% |
| 2016 Q1 | 16.91 Million CNY | -54.41% |
| 2015 FY | 117.63 Million CNY | -11.41% |
| 2015 Q1 | 14.71 Million CNY | -74.43% |
| 2015 Q2 | 39.69 Million CNY | 169.67% |
| 2015 Q3 | 26.11 Million CNY | -34.2% |
| 2015 Q4 | 37.11 Million CNY | 42.09% |
| 2014 Q2 | 37.29 Million CNY | 204.62% |
| 2014 FY | 132.78 Million CNY | 67.5% |
| 2014 Q4 | 57.56 Million CNY | 124.18% |
| 2014 Q3 | 25.67 Million CNY | -31.15% |
| 2014 Q1 | 12.24 Million CNY | -21.12% |
| 2013 Q3 | 20.39 Million CNY | -37.71% |
| 2013 FY | 79.27 Million CNY | 34.93% |
| 2013 Q1 | 10.61 Million CNY | -13.38% |
| 2013 Q2 | 32.74 Million CNY | 208.39% |
| 2013 Q4 | 15.52 Million CNY | -23.89% |
| 2012 Q4 | 12.25 Million CNY | -9.95% |
| 2012 Q2 | 32.84 Million CNY | 267.18% |
| 2012 FY | 58.75 Million CNY | 15.45% |
| 2012 Q1 | 8.94 Million CNY | -22.19% |
| 2012 Q3 | 13.61 Million CNY | -58.55% |
| 2011 Q1 | 13.89 Million CNY | 73.84% |
| 2011 Q2 | 16.11 Million CNY | 16.0% |
| 2011 Q3 | 9.39 Million CNY | -41.68% |
| 2011 Q4 | 11.49 Million CNY | 22.32% |
| 2011 FY | 50.89 Million CNY | 41.8% |
| 2010 Q1 | 8.92 Million CNY | 0.0% |
| 2010 FY | 35.89 Million CNY | 62.58% |
| 2010 Q3 | 6.43 Million CNY | -48.69% |
| 2010 Q4 | 7.99 Million CNY | 24.16% |
| 2010 Q2 | 12.54 Million CNY | 40.52% |
| 2009 FY | 22.07 Million CNY | 47.28% |
| 2009 Q2 | 5.39 Million CNY | 0.0% |
| 2008 FY | 14.98 Million CNY | 21.09% |
| 2007 FY | 12.37 Million CNY | 307.57% |
| 2006 FY | 3.03 Million CNY | -62.12% |
| 2005 FY | 8.01 Million CNY | -6.81% |
| 2004 FY | 8.6 Million CNY | -1.19% |
| 2003 FY | 8.7 Million CNY | -17.76% |
| 2002 FY | 10.58 Million CNY | -61.34% |
| 2001 FY | 27.38 Million CNY | -19.66% |
| 2000 FY | 34.08 Million CNY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pak Fah Yeow International Limited | 105.03 Million HKD | -41.097% |
| Grand Pharmaceutical Group Limited | 1.87 Billion HKD | 92.117% |
| Extrawell Pharmaceutical Holdings Limited | -162.94 Million HKD | 190.953% |
| Wai Yuen Tong Medicine Holdings Limited | -15.35 Million HKD | 1065.141% |
| Qianhai Health Holdings Limited | -52.7 Million HKD | 381.201% |
| Lee's Pharmaceutical Holdings Limited | 16.69 Million HKD | -787.573% |
| Essex Bio-Technology Limited | 275.25 Million HKD | 46.157% |
| Tongfang Kontafarma Holdings Limited | -28.84 Million HKD | 613.84% |
| PuraPharm Corporation Limited | -106.08 Million HKD | 239.711% |
| SSY Group Limited | 1.31 Billion HKD | 88.76% |
| JBM (Healthcare) Limited | 130.46 Million HKD | -13.601% |
| Jacobson Pharma Corporation Limited | 266.96 Million HKD | 44.485% |
| China Resources Pharmaceutical Group Limited | 3.85 Billion HKD | 96.155% |